Conference CallMy key take aways. Without being said...ONC is now a Pancreatic Cancer Company with a possible Q1 2025 enrollment.
ONC demoted Breast Cancer to a Phase 2 opportunity. The target population for pela is subjugate to the evolving ADC treatments. Specifically individuals dropping out of first line ADC treatment. They suggested more details on Breast Cancer forethcoming in three months. The good is we have a clearer understanding of path and timeline for pancreatic. Markets will like this.
The bad...market potential and risking got hammerred by Breast Cancer demotion.
I cant believe the board didnt clean house after last years Breast Cancer fiasco. The multi year delay to complete AWARE. They no longer talk about using biomarkers. And the failure to include tylenol treatment protocals for individuals sufferring flu like symptoms. They lost the best half of responding population.